S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study|
|Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine|
|Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate|
|NICE Recommends Commissioning of Eculizumab (Soliris®) for All Patients with aHUS in England|
|U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma|
|Photo Release -- 3D Systems and United Nude Launch Line of 3D-Printed Shoes & 3D Printing Retail Experience in NYC|
|European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)|
|Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation|
|BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results|
|Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results|
Click above to view more mutual fund data and stats for rem - Remgro Ltd.